Detalhe da pesquisa
1.
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
N Engl J Med
; 381(10): 933-944, 2019 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31483964
2.
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Invest New Drugs
; 33(1): 247-53, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25388940
3.
Biofilm disruption and bactericidal activity of aqueous ozone coupled with ultrasonic dental scaling.
JADA Found Sci
; 1: 100003, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-37520742
4.
Disinfection of Pseudomonas aeruginosa from N95 respirators with ozone: a pilot study.
BMJ Open Respir Res
; 8(1)2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33431507
5.
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 8(2): 246-259, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30091852
6.
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
Clin Cancer Res
; 17(2): 363-71, 2011 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21224368